Clinical trials: Blood Disease
Multiple Myeloma
Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma
The purpose of this study is to evaluate time to progression, overall survival, response rate and safety for the two open-label treatment groups; DOXIL/CAELYX in combination with VELCADE vs. VELCADE monotherapy.
- Trial name
- NCT00103506
- Testing
- Bortezomib (VELCADE), Doxorubicin hydrochloride (DOXIL/CAELYX)
- Where
- 108 sites in United States, Argentina and 15 more
- Volunteers
- 646 people
- Sponsor
- Janssen Research & Development, LLC
HIV Infections
A Study to Evaluate the Safety and Effectiveness of a New Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), (+)-Calanolide A, in HIV-Positive Patients Who Have Never Received Anti-HIV Treatment
The purpose of this study is to test the safety and effectiveness of a new non-nucleoside reverse transcriptase inhibitor (NNRTI), (+)-calanolide A, in HIV-positive patients who have never received anti-HIV treatment.
- Trial name
- NCT00002243
- Testing
- Calanolide A
- Where
- 9 sites in United States
- Volunteers
- 32 people
- Sponsor
- Sarawak MediChem Pharmaceuticals
Chronic Hepatitis C
A Study to Evaluate the Safety, Antiviral Effect, and Pharmacokinetics of Celgosivir in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C
The objective of this study is to undertake an initial evaluation of the safety, tolerability, antiviral effect, and pharmacokinetics of celgosivir in combination with peginterferon alfa-2b and ribavirin in patients with chronic…
- Trial name
- NCT00332176
- Testing
- Celgosivir, Peginterferon alfa 2b + ribavirin
- Where
- 3 sites in Canada
- Volunteers
- 50 people
- Sponsor
- BioWest Therapeutics Inc
Acute Myeloid Leukemia
A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia
This is a open label, phase Ib/II study. All patients are diagnosed with AML, Eastern Cooperative Oncology Group (ECOG) performance status 0-3.
- Trial name
- NCT04980885
- Testing
- AK117, Azacitidine
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Akeso
Chronic Hepatitis C
A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects
The primary purpose of this study is to evaluate the safety profile and tolerability of single oral doses of BMS-791325 in subjects with chronic hepatitis C infection
- Trial name
- NCT00664625
- Testing
- BMS-791325
- Where
- 6 sites in United States, Argentina
- Volunteers
- 24 people
- Sponsor
- Bristol-Myers Squibb
Multiple Myeloma
A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma
The primary purpose of this dose escalation study is to estimate the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) of LGH447 as a single agent when administered orally once daily to adult patients with…
- Trial name
- NCT01456689
- Testing
- LGH447, midazolam
- Where
- 8 sites in United States, Germany and 2 more
- Volunteers
- 79 people
- Sponsor
- Novartis Pharmaceuticals
Adult Acute Myeloid Leukemia
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
This is a multi-center, randomized, double-blinded, placebo controlled trial.
- Trial name
- MO-TRANS (NCT05429632)
- Testing
- mocravimod
- Where
- 111 sites in United States, Argentina and 12 more
- Volunteers
- 366 people
- Sponsor
- Priothera SAS
Chronic Hepatitis b
Ethnobridging Study in Healthy Volunteers, Chinese and Japanese Subjects
This is a single center, open-label, 3-Cohort, parallel, single-dose, study to evaluate the PK, safety, and tolerability of ATI-2173 50 mg administered orally in Japanese, Chinese, and Non-Asian healthy subjects incorporating a…
- Trial name
- NCT05298332
- Testing
- ATI-2173 50 mg
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Antios Therapeutics, Inc
HIV Infections
Safety Study of Tipranavir Co-administered With Low-dose Ritonavir (TPV/r) in Patients With Advanced HIV-1 Infection and Limited Treatment Options
This study evaluated the safety and tolerability of tipranavir to improve treatment options for HIV type 1-infected patients who have been previously treated and whose treatment is no longer effective.
- Trial name
- NCT00144287
- Testing
- Tipranavir/Ritonavir
- Where
- 53 sites in Germany
- Volunteers
- 255 people
- Sponsor
- Boehringer Ingelheim
Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia
A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
This study is a single-center, open-label, dose-escalation study to observe the safety and efficacy of different doses of CAR-GPRC5D in patients with R/R MM or Plasma Cell Leukemia.
- Trial name
- NCT05759793
- Testing
- CAR-GPRC5D
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Nanjing IASO Biotechnology Co., Ltd.
Menorrhagia, Heavy Menstrual Bleeding
Librata Endometrial Ablation Device Treatment to Reduce Menstrual Blood Loss
The objective of this study is to evaluate the safety and effectiveness of the endometrial ablation device Librata in reducing menstrual blood loss at 12 months post-treatment when used in pre-menopausal women with menorrhagia…
- Trial name
- LEADER (NCT03725306)
- Testing
- Librata
- Volunteers
- 200 people
- Sponsor
- LiNA Medical
Myelodysplastic Syndrome, MDS
Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA
The study's primary objective [in a population of patients with MDS after failure of treatment with azacitidine (AZA) or decitabine (DAC)], is to compare the overall survival (OS) of patients in the rigosertib group vs the…
- Conditions
- Myelodysplastic Syndrome, MDS, Refractory Anemia With Excess Blasts, RAEB
- Trial name
- INSPIRE (NCT02562443)
- Testing
- rigosertib, Any approved or standard-of-care therapy, best supportive care (BSC)
- Where
- 158 sites in United States, Australia and 20 more
- Volunteers
- 372 people
- Sponsor
- Traws Pharma, Inc.
Hypertension
Impact of Pacing Site and AV Delay on Blood Pressure in Hypertensive Patients
The purpose of this study is to test whether the A-V sequential pacing strategy shown to effectively reduce blood pressure in a dog model of hypertension also reduces blood pressure acutely in patients with hypertension (systolic…
- Trial name
- NCT02382484
- Testing
- A dual chamber pacing system (BackBeat Medical)
- Where
- China
- Volunteers
- 19 people
- Sponsor
- BackBeat Medical Inc
HIV Infections
Efficacy of Nevirapine Compared to ZDV + 3TC Administered in Labor and Again at Postdelivery in HIV Positive Women
The primary objective of the study was to evaluate the efficacy of nevirapine versus ZDV+3TC (Zidovudine + Lamivudine), when administered in labor and again at postdelivery, in reducing peripartum mother to child transmission of…
- Trial name
- NCT02181933
- Testing
- Nevirapine, Zidovudine (ZDV), Lamivudine (3TC)
- Volunteers
- 2,648 people
- Sponsor
- Boehringer Ingelheim
Lymphoma, Chronic Lymphocytic Leukemia
A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax).
This is a single dose, open-label, single or multiple center study to determine the interaction of ketoconazole with ABT-263 in approximately 12 subjects with cancer.
- Conditions
- Lymphoma, Chronic Lymphocytic Leukemia, Solid Tumors
- Trial name
- NCT01021358
- Testing
- ABT-263, Ketoconazole
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Abbott
Myelofibrosis (MF)
Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis
Myelofibrosis (MF) is a bone marrow illness that affects blood-forming tissues in the body. MF disturbs the body's normal production of blood cells, causing extensive scarring in the bone marrow.
- Trial name
- NCT04454658
- Testing
- ABBV-744, Navitoclax, Ruxolitinib
- Where
- 43 sites in United States, Argentina and 12 more
- Volunteers
- 21 people
- Sponsor
- AbbVie
Hematologic Malignancy, Acute Myeloid Leukemia
A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351
This study evaluates the pharmacokinetics and safety of CPX-351 in patients with moderate or severe renal impairment.
- Conditions
- Hematologic Malignancy, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia
- Trial name
- NCT03555955
- Testing
- CPX-351
- Where
- 13 sites in United States, Canada
- Volunteers
- 21 people
- Sponsor
- Jazz Pharmaceuticals
Acute Myeloid Leukemia, Adult, Myelodysplastic Syndromes
First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients
This First In Human (FIH) study is a prospective, open-label, multicenter, Phase 1 study, with a dose escalation design, followed by an optimized design.
- Trial name
- ODYSSEY (NCT05601726)
- Testing
- ABD-3001
- Where
- 3 sites in France
- Volunteers
- 36 people
- Sponsor
- Advanced BioDesign
Iron Status
Effect of Young Child Formula on Iron Status in Children 1-3 Years of Age.
This study evaluates the effect of young child formula in children 1-3 years of age. Subjects will receive either test or control product.
- Trial name
- NCT07324135
- Testing
- Nutritional product
- Where
- Indonesia
- Volunteers
- 466 people, healthy volunteers welcome
- Sponsor
- Nutricia Research
Beta-Thalassemia
A Clinical Study Evaluating the Safety and Efficacy of CS-101 in Treating Subjects With β-thalassemia
The goal of this open label, single-arm clinical study is to learn about the safety and efficacy of CS-101 in treating β-thalassemia.
- Trial name
- NCT06024876
- Testing
- CS-101
- Where
- China
- Volunteers
- 5 people
- Sponsor
- CorrectSequence Therapeutics Co., Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.